Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Fighting in a wasteland: deleterious metabolites and antitumor immunity
McLane J. Watson, Greg M. Delgoffe
McLane J. Watson, Greg M. Delgoffe
Published January 18, 2022
Citation Information: J Clin Invest. 2022;132(2):e148549. https://doi.org/10.1172/JCI148549.
View: Text | PDF
Review Series Article has an altmetric score of 11

Fighting in a wasteland: deleterious metabolites and antitumor immunity

  • Text
  • PDF
Abstract

As cancers progress, they produce a local environment that acts to redirect, paralyze, exhaust, or otherwise evade immune detection and destruction. The tumor microenvironment (TME) has long been characterized as a metabolic desert, depleted of essential nutrients such as glucose, oxygen, and amino acids, that starves infiltrating immune cells and renders them dysfunctional. While not incorrect, this perspective is only half the picture. The TME is not a metabolic vacuum, only consuming essential nutrients and never producing by-products. Rather, the by-products of depleted nutrients, “toxic” metabolites in the TME such as lactic acid, kynurenine, ROS, and adenosine, play an important role in shaping immune cell function and cannot be overlooked in cancer immunotherapy. Moreover, while the metabolic landscape is distinct, it is not unique, as these toxic metabolites are encountered in non-tumor tissues, where they evolutionarily shape immune cells and their response. In this Review, we discuss how depletion of essential nutrients and production of toxic metabolites shape the immune response within the TME and how toxic metabolites can be targeted to improve current cancer immunotherapies.

Authors

McLane J. Watson, Greg M. Delgoffe

×

Total citations by year

Year: 2025 2024 2023 2022 Total
Citations: 5 5 7 4 21
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (21)

Title and authors Publication Year
Lactate and lactylation in cancer
Chen J, Huang Z, Chen Y, Tian H, Chai P, Shen Y, Yao Y, Xu S, Ge S, Jia R
Signal Transduction and Targeted Therapy 2025
Reprogramming of Glucose Metabolism by Nanocarriers to Improve Cancer Immunotherapy: Recent Advances and Applications
Jiang K, Liu H, Chen X, Wang Z, Wang X, Gu X, Tong Y, Ba X, He Y, Wu J, Deng W, Wang Q, Tang K
International Journal of Nanomedicine 2025
Tumour interstitial fluid-enriched phosphoethanolamine suppresses T cell function.
Wang Y, Wilfahrt D, Jonker P, Lontos K, Cai C, Cameron B, Xie B, Peralta RM, Schoedel ER, Gunn WG, AminiTabrizi R, Shah H, Rivadeneira DB, Muir A, Delgoffe GM
Nature cell biology 2025
The integrated single-cell analysis interpret the lactate metabolism-driven immune suppression in triple-negative breast cancer.
Gao X, Wang T, Liu C, Li Y, Zhang W, Zhang M, Yao Y, Gao C, Liu R, Sun C
Discover oncology 2025
Characterization of the aryl hydrocarbon receptor as a potential candidate to improve cancer T cell therapies.
De Castro V, Abdellaoui O, Dehecq B, Ndao B, Mercier-Letondal P, Dauvé A, Garnache-Ottou F, Adotévi O, Loyon R, Godet Y
Cancer immunology, immunotherapy : CII 2025
Integrated longitudinal multi-omics study identifies immune programs associated with COVID-19 severity and mortality in 1152 hospitalized participants
Jeremy Gygi, Cole Maguire, Ravi K. Patel, Pramod Shinde, Anna Konstorum, Casey Shannon, Leqi Xu, Annmarie Hoch, Naresh Jayavelu, Elias Haddad, Elaine Reed, Monica Kraft, Grace McComsey, Jordan Metcalf, Al Ozonoff, Denise Esserman, Charles Cairns, Nadine Rouphael, Steven Bosinger, Seunghee Kim-Schulze, Florian Krammer, Lindsey Rosen, Harm Bakel, Michael R. Wilson, Walter Eckalbar, Holden Maecker, Charles Langelier, Hanno Steen, Matthew C. Altman, Ruth R Montgomery, Ofer Levy, Esther Melamed, Bali Pulendran, Joann Diray-Arce, Kinga Smolen, Gabriela Fragiadakis, Patrice M. Becker, Alison Augustine, Rafick Sekaly, Lauren Ehrlich, Slim Fourati, Bjoern Peters, Steven H. Kleinstein, Leying Guan
Journal of Clinical Investigation 2024
Glycolysis Induced by METTL14 Is Essential for Macrophage Phagocytosis and Phenotype in Cervical Cancer
Wang B, Mao Z, Ye J, Jiao X, Zhang T, Wang Q, Han S, Zhang Y, Wang C, Dong T, Cui B
2024
CRISPR-Cas gene knockouts to optimize engineered T cells for cancer immunotherapy.
De Castro V, Galaine J, Loyon R, Godet Y
Cancer Gene Therapy 2024
Immunogenic cell death: A new strategy to enhancing cancer immunotherapy
Dou L, Fang Y, Yang H, Ai G, Shen N
Human Vaccines & Immunotherapeutics 2024
Aryl hydrocarbon receptor as a drug target in advanced prostate cancer therapy – obstacles and perspectives
Procházková J, Kahounová Z, Vondráček J, Souček K
Transcription 2024
Therapeutic targeting of tumour myeloid cells.
Barry ST, Gabrilovich DI, Sansom OJ, Campbell AD, Morton JP
Nature reviews. Cancer 2023
CDK4/6 inhibitors and the pRB-E2F1 axis suppress PVR and PD-L1 expression in triple-negative breast cancer.
Shrestha M, Wang DY, Ben-David Y, Zacksenhaus E
Oncogenesis 2023
Myeloid-derived suppressor cells impair CD4+ T cell responses during chronic Staphylococcus aureus infection via lactate metabolism
Goldmann O, Medina E
Cellular and Molecular Life Sciences 2023
Leveraging high-resolution omics data for predicting responses and adverse events to immune checkpoint inhibitors.
Limeta A, Gatto F, Herrgård MJ, Ji B, Nielsen J
Computational and Structural Biotechnology Journal 2023
Amino acid metabolism reprogramming: shedding new light on T cell anti-tumor immunity
Zheng Y, Yao Y, Ge T, Ge S, Jia R, Song X, Zhuang A
Journal of experimental & clinical cancer research : CR 2023
PDK4-dependent hypercatabolism and lactate production of senescent cells promotes cancer malignancy.
Dou X, Fu Q, Long Q, Liu S, Zou Y, Fu D, Xu Q, Jiang Z, Ren X, Zhang G, Wei X, Li Q, Campisi J, Zhao Y, Sun Y
Nature metabolism 2023
Itaconate promotes hepatocellular carcinoma progression by epigenetic induction of CD8+ T-cell exhaustion
Gu X, Wei H, Suo C, Shen S, Zhu C, Chen L, Yan K, Li Z, Bian Z, Zhang P, Yuan M, Yu Y, Du J, Zhang H, Sun L, Gao P
Nature Communications 2023
The Evasion Mechanisms of Cancer Immunity and Drug Intervention in the Tumor Microenvironment
Kim SK, Cho SW
Frontiers in pharmacology 2022
Potential of mRNA vaccines to become versatile cancer vaccines.
Tsao SY
World journal of clinical oncology 2022
MITOCHONDRIA IN CANCER: CLEAN WINDMILLS OR STRESSED TINKERERS?
Altieri DC
Trends in Cell Biology 2022
Proton pump inhibitors display anti‐tumour potential in glioma
Li B, Liu Y, Sun S
Cell Proliferation 2022

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Posted by 17 X users
45 readers on Mendeley
See more details